Skip to main content

Together we are beating cancer

Donate now

Jacob Smith

Jacob is a digital news officer at Cancer Research UK. He studied biochemistry at the University of Exeter and subsequently completed a Master’s in science communication at Imperial College London. He joined the digital news team in March 2022, writing for the news site and contributing to our podcast, That Cancer Conversation.
Jacob Smith
Showing 12 out of 66 results
A black woman at a doctor's appointment

A new study has revealed that Black women from Caribbean and African backgrounds are more likely to be diagnosed with certain types of cancer at later stages, when treatment is less likely to be successful.  A new study has revealed that Black women from Caribbean and African backgrounds are more likely to be diagnosed with certain types of cancer at later stages, when treatment is less likely to be successful. 

by Jacob Smith | Analysis | 27 January 2023

27 January 2023

A person holding a lit cigarette

The UK government is almost a decade behind achieving its target for England to be smokefree by 2030, a new report reveals. The UK government is almost a decade behind achieving its target for England to be smokefree by 2030, a new report reveals.

by Jacob Smith | News | 29 December 2022

29 December 2022

Left to right: Emma Colliver, Dr William Hill and Dr Emilia Lim

We chatted to three researchers working on TRACERx, Dr Emilia Lim, Dr William Hill and Emma Colliver about their work, what a day in their lives looks like, and how their paths have led to where they are today.  We chatted to three researchers working on TRACERx, Dr Emilia Lim, Dr William Hill and Emma Colliver about their work, what a day in their lives looks like, and how their paths have led to where they are today. 

by Jacob Smith | Interview | 13 December 2022

13 December 2022

An image of a chest x-ray showing some signs of disease

Up to 14% of people with lung cancer in the UK have never smoked. New research funded by us reveals why non-smokers face delays in getting diagnosed with lung cancer Up to 14% of people with lung cancer in the UK have never smoked. New research funded by us reveals why non-smokers face delays in getting diagnosed with lung cancer

by Jacob Smith | In depth | 25 November 2022

25 November 2022

T cell

Researchers in Southampton have found a way to improve the effectiveness of immunotherapy in cancers that are resistant by repurposing existing drugs Researchers in Southampton have found a way to improve the effectiveness of immunotherapy in cancers that are resistant by repurposing existing drugs

by Jacob Smith | Analysis | 11 November 2022

11 November 2022

The House of Parliament in London

Research from the International Cancer Benchmarking Partnership has found a link between cancer policy consistency over time and survival for six cancer types Research from the International Cancer Benchmarking Partnership has found a link between cancer policy consistency over time and survival for six cancer types

by Jacob Smith | Analysis | 1 November 2022

1 November 2022

A 3D illustration of cancer cells

Research from our Cambridge Institute has shown us that metastasis isn’t a process unique to cancer, revolutionising the way we think about cell dissemination.  Research from our Cambridge Institute has shown us that metastasis isn’t a process unique to cancer, revolutionising the way we think about cell dissemination. 

by Jacob Smith | Analysis | 18 October 2022

18 October 2022

A graphic depicting a shadow in the shape of DNA overlaying strings of genetic code

A team of researchers has developed a new tool to identify mutational signatures in cancer DNA that's quickly establishing itself as the best of the best.   A team of researchers has developed a new tool to identify mutational signatures in cancer DNA that's quickly establishing itself as the best of the best.  

by Jacob Smith | Analysis | 12 October 2022

12 October 2022

A prostate cancer cell.

NICE does not recommend olaparib (Lynparza) for people with a type of advanced prostate cancer, as the treatment is not deemed cost-effective NICE does not recommend olaparib (Lynparza) for people with a type of advanced prostate cancer, as the treatment is not deemed cost-effective

by Jacob Smith | News | 13 September 2022

13 September 2022